{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:37:41Z","timestamp":1793090261347,"version":"4.5.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020581","name":"AIRC Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105607","type":"journal-article","created":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:28:29Z","timestamp":1789914509000},"page":"105607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Emerging patterns of kidney cancer in young adults: where do we stand?"],"prefix":"10.1016","volume":"227","author":[{"given":"Paola","family":"Troisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0667-5458","authenticated-orcid":false,"given":"Denis","family":"Occhipinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Ligato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Sardaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5237-0888","authenticated-orcid":false,"given":"Riccardo","family":"Campi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Merenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4705-3340","authenticated-orcid":false,"given":"Natalia","family":"Cappoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0624-9814","authenticated-orcid":false,"given":"Daniela","family":"Arduini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Di Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4508-869X","authenticated-orcid":false,"given":"Seyed Koosha","family":"Moosavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0464-0788","authenticated-orcid":false,"given":"Nazario","family":"Foschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Sighinolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pierconti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3283-4339","authenticated-orcid":false,"given":"Chiara","family":"Ciccarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Iacovelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.critrevonc.2026.105607_bib1","doi-asserted-by":"crossref","first-page":"5735","DOI":"10.1016\/j.cell.2024.07.038","article-title":"A genetic basis for sex differences in Xp11 translocation renal cell carcinoma","volume":"187","author":"Achom","year":"2024","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105607_bib2","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1470-2045(23)00276-0","article-title":"Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial","volume":"24","author":"Albiges","year":"2023","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105607_bib3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/oncolo\/oyac262","article-title":"Immune checkpoint therapy combinations in adult advanced MiT family translocation renal cell carcinomas","volume":"28","author":"Alhalabi","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2026.105607_bib4","doi-asserted-by":"crossref","DOI":"10.23736\/S2724-6051.25.06760-6","article-title":"Clinical and technical insights on KIM-1: what we need to know","author":"Arduini","year":"2026","journal-title":"Minerva Urol. Nephrol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105607_bib5","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1097\/PAS.0000000000000720","article-title":"TFEB-amplified renal cell carcinomas: an aggressive molecular subset demonstrating variable melanocytic marker expression and morphologic heterogeneity","volume":"40","author":"Argani","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105607_bib6","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.juro.2013.08.021","article-title":"Do young patients with renal cell carcinoma feature a distinct outcome after surgery? A comparative analysis of patient age based on the multinational CORONA database","volume":"191","author":"Aziz","year":"2014","journal-title":"J. Urol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105607_bib7","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.annonc.2025.03.016","article-title":"Interdisciplinary renal cell carcinoma working group of the DKG (IAGN). Prospective randomized phase-II trial of ipilimumab\/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial","volume":"36","author":"Bergmann","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105607_bib8","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105607_bib9","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/s41588-024-01800-z","article-title":"Saturation genome editing maps the functional spectrum of pathogenic VHL alleles","volume":"56","author":"Buckley","year":"2024","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105607_bib10","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.eururo.2022.08.019","article-title":"Epidemiology of renal cell carcinoma: 2022 update","volume":"82","author":"Bukavina","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2026.105607_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048489","article-title":"Impact of age on the cancer-specific survival of patients with localized renal cell carcinoma: Martingale residual and competing risks analysis","volume":"7","author":"Cai","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2026.105607_bib12","doi-asserted-by":"crossref","first-page":"487","DOI":"10.5858\/2005-129-487-RNIYAA","article-title":"Renal neoplasms in younger adults: Analysis of 112 tumors from a single institution according to the new 2004 World Health Organization classification and 2002 American Joint Committee on Cancer staging system","volume":"129","author":"Cao","year":"2005","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"suppl 7","key":"10.1016\/j.critrevonc.2026.105607_bib13","article-title":"Adjuvant pembrolizumab plus belzutifan versus pembrolizumab for clear cell renal cell carcinoma (ccRCC): the randomized phase 3 LITESPARK-022 study","volume":"44","author":"Choueiri","year":"2026","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105607_bib14","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105607_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ctrv.2016.07.003","article-title":"The prospect of precision therapy for renal cell carcinoma","volume":"49","author":"Ciccarese","year":"2016","journal-title":"Cancer Treat. Rev."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105607_bib16","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(25)00153-6","article-title":"Belzutifan in von Hippel-Lindau disease","volume":"26","author":"Ciccarese","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105607_bib17","first-page":"438.e23","article-title":"Clinical characteristics of renal cell carcinoma in patients under the age of 40","volume":"39","author":"Douglas","year":"2021","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"10.1016\/j.critrevonc.2026.105607_bib18","unstructured":"European Medicines Agency. Welireg. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/welireg#:~:text=information%20on%20Welireg-,Overview,types%20of%20VEGF%2Dtargeted%20medicines."},{"key":"10.1016\/j.critrevonc.2026.105607_bib19","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-22-1054","article-title":"FDA approval summary: Belzutifan for von Hippel-Lindau disease associated tumors","author":"Fallah","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105607_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100096","article-title":"Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE)","volume":"6","author":"Ferrari","year":"2021","journal-title":"ESMO Open."},{"key":"10.1016\/j.critrevonc.2026.105607_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.784993","article-title":"Xp11.2 translocation renal cell carcinoma with TFE3 rearrangement: Distinct morphological features and prognosis with different fusion partners","volume":"11","author":"Ge","year":"2021","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105607_bib22","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1097\/PAS.0000000000000292","article-title":"Succinate dehydrogenase (SDH)-deficient renal carcinoma: A morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients","volume":"38","author":"Gill","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105607_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics14171909","article-title":"Genetics, pathophysiology, and current challenges in von Hippel\u2013Lindau disease therapeutics","volume":"14","author":"G\u00f3mez-Virgilio","year":"2024","journal-title":"Diagnostics"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105607_bib24","article-title":"The WHO 2022 classification of renal neoplasms (5th edition): Salient updates","volume":"16","author":"Goswami","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.critrevonc.2026.105607_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103750","article-title":"Targeting hypoxia-inducible factor pathways in sporadic and von Hippel\u2013Lindau syndrome-related kidney cancers","volume":"176","author":"Iacovelli","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105607_bib26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ucl.2023.01.010","article-title":"Diseases of hereditary renal cell cancers","volume":"50","author":"Iliopoulos","year":"2023","journal-title":"Urol. Clin. North. Am."},{"key":"10.1016\/j.critrevonc.2026.105607_bib27","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel\u2013Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"New. Engl. J. Med."},{"issue":"5_suppl","key":"10.1016\/j.critrevonc.2026.105607_bib28","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.443","article-title":"Lenvatinib plus tislelizumab as first-line therapy for advanced fumarate hydratase\u2013deficient renal cell carcinoma: a single-center, single-arm, phase II study","volume":"43","author":"Kong","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105607_bib29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10585-025-10368-9","article-title":"Targeting metabolic and epigenetic reprogramming in metastatic fumarate hydratase-deficient renal cell carcinoma","volume":"42","author":"K\u00fchrer","year":"2025","journal-title":"Clin. Exp. Metastasis"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105607_bib30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5114\/pjp.2016.59227","article-title":"Review of succinate dehydrogenase-deficient renal cell carcinoma with focus on clinical and pathobiological aspects","volume":"67","author":"Kuroda","year":"2016","journal-title":"Pol. J. Pathol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105607_bib31","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1007\/s12253-019-00792-0","article-title":"Clinicopathological findings on 28 cases with XP11.2 renal cell carcinoma","volume":"26","author":"Kuthi","year":"2020","journal-title":"Pathol. Oncol. Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105607_bib32","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.euo.2024.07.002","article-title":"Clinical characteristics, management, and outcomes of patients with renal medullary carcinoma: a single-center retrospective analysis of 135 patients","volume":"8","author":"Lebenthal","year":"2025","journal-title":"Eur. Urol. Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105607_bib33","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.21.01944","article-title":"Phase II trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates","volume":"40","author":"Lee","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105607_bib34","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1158\/1078-0432.CCR-13-0304","article-title":"Molecular pathways: fumarate hydratase\u2013deficient kidney cancer\u2014Targeting the Warburg effect in cancer","volume":"19","author":"Linehan","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105607_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155459","article-title":"Succinate dehydrogenase A-deficient renal cell carcinoma: a rare renal tumor distinct from typical succinate dehydrogenase-deficient renal cell carcinoma","volume":"261","author":"Liu","year":"2024","journal-title":"Pathol. Res. Pract."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105607_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102446","article-title":"Analysis of clinicopathologic features and imaging findings of TFE3-rearranged renal cell carcinoma","volume":"23","author":"Liu","year":"2025","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105607_bib37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.urology.2025.07.031","article-title":"Clinical, pathologic, and genetic correlates of nuclear grade in von Hippel-Lindau-associated renal cell carcinoma","volume":"204","author":"Loebach","year":"2025","journal-title":"Urology"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105607_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100873","article-title":"TRIM63 overexpression in FISH-negative MiTF family altered renal cell carcinoma (MiTF RCC)","volume":"38","author":"Mannan","year":"2025","journal-title":"Mod. Pathol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105607_bib39","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.ctrv.2015.07.002","article-title":"Metabolic alterations in renal cell carcinoma","volume":"41","author":"Massari","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105607_bib40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41698-018-0053-2","article-title":"SDH-deficient renal cell carcinoma associated with biallelic mutation in succinate dehydrogenase A: comprehensive genetic profiling and its relation to therapy response","volume":"2","author":"McEvoy","year":"2018","journal-title":"Precis. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105607_bib41","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 World Health Organization classification of tumours of the urinary system and male genital organs\u2014part a: renal, penile, and testicular tumours","volume":"82","author":"Moch","year":"2022","journal-title":"Eur. Urol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105607_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002312","article-title":"Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors","volume":"7","author":"Moore","year":"2011","journal-title":"PLoS. Genet."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105607_bib43","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"CLEAR Trial Investigators. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105607_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(26)01089-5","article-title":"Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial","author":"Motzer","year":"2026","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105607_bib45","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105607_bib46","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105607_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clgc.2018.09.005","article-title":"Updated recommendations on the diagnosis, management, and clinical trial eligibility criteria for patients with renal medullary carcinoma","volume":"17","author":"Msaouel","year":"2019","journal-title":"Clin. Genitourin. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105607_bib48","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41379-018-0017-7","volume":"31","author":"Muller","year":"2018","journal-title":"Mod. Pathol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105607_bib49","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1158\/1535-7163.MCT-24-0225","article-title":"Targeting NAD+ metabolism vulnerability in FH-deficient hereditary leiomyomatosis and renal cell carcinoma with the novel NAMPT inhibitor OT-82","volume":"24","author":"Najera","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105607_bib50","unstructured":"National Cancer Institute. SEER Cancer Stat Facts: Kidney and Renal Pelvis Cancer. Surveillance, Epidemiology, and End Results Program. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html."},{"key":"10.1016\/j.critrevonc.2026.105607_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2020.101762","article-title":"Renal cell carcinoma incidence rates and trends in young adults aged 20\u201339 years","volume":"67","author":"Palumbo","year":"2020","journal-title":"Cancer Epidemiol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105607_bib52","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jaad.2017.01.023","article-title":"Hereditary leiomyomatosis and renal cell cancer syndrome: an update and review","volume":"77","author":"Patel","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105607_bib53","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105607_bib54","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.3390\/ijms26073431","article-title":"Kidney injury molecule-1 as a biomarker for renal cancer: current insights and future perspectives-a narrative review","volume":"26","author":"Puia","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105607_bib55","first-page":"010","article-title":"Is immunohistochemistry enough to diagnose Xp11.2 renal cell carcinoma?","volume":"6","author":"Ribeiro","year":"2021","journal-title":"Int. Arch. Transl. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105607_bib56","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1053\/j.semdp.2023.11.001","article-title":"Hereditary succinate dehydrogenase-deficient renal cell carcinoma","volume":"41","author":"Rogala","year":"2024","journal-title":"Semin. Diagn. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105607_bib57","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1097\/01.ju.0000125487.96469.2e","article-title":"Young age is an independent prognostic factor for survival of sporadic renal cell carcinoma","volume":"171","author":"S\u00e0nchez-Ortiz","year":"2004","journal-title":"J. Urol."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105607_bib58","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1158\/1078-0432.CCR-18-1496","article-title":"KIM-1 as a blood-based marker for early detection of kidney cancer: a prospective nested case-control study","volume":"24","author":"Scelo","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105607_bib59","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1016\/j.clgc.2019.09.012","article-title":"Oncologic outcomes in young adults with kidney cancer treated during the targeted therapy era","volume":"18","author":"Sierra","year":"2020","journal-title":"Clin. Genitourin. Cancer"},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105607_bib60","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1056\/NEJMoa2200900","article-title":"Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer","volume":"392","author":"Srinivasan","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105607_bib61","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1470-2045(25)00099-3","article-title":"Belzutifan for von Hippel\u2013Lindau disease\u2013associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months\u2019 follow-up from a single-arm, phase 2 study","volume":"26","author":"Srinivasan","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105607_bib62","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/medsci11030046","article-title":"Selective HIF2A inhibitors in the management of clear cell renal cancer and von Hippel\u2013Lindau-disease-associated tumors","volume":"11","author":"Su\u00e1rez","year":"2023","journal-title":"Med. Sci."},{"key":"10.1016\/j.critrevonc.2026.105607_bib63","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1158\/1078-0432.CCR-20-3788","article-title":"Integrated molecular characterization of fumarate hydratase\u2013deficient renal cell carcinoma","volume":"27","author":"Sun","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105607_bib64","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.eururo.2006.10.025","article-title":"Renal cell carcinoma in adults 40 years old or less: Young age is an independent prognostic factor for cancer-specific survival","volume":"51","author":"Taccoen","year":"2007","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105607_bib65","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/his.13672","article-title":"Pathological staging of renal cell carcinoma: a review of 300 consecutive cases with emphasis on retrograde venous invasion","volume":"73","author":"Taneja","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.critrevonc.2026.105607_bib66","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.4526","article-title":"CA-62: A new biomarker for the detection of early-stage renal cell carcinoma","volume":"42","author":"Tcherkassova","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105607_bib67","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.euo.2021.09.005","article-title":"Germline variants identified in patients with early-onset renal cell carcinoma referred for germline genetic testing","volume":"4","author":"Truong","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105607_bib68","doi-asserted-by":"crossref","first-page":"192","DOI":"10.5414\/CN109619","article-title":"Renal cell carcinoma associated with Xp11.2 translocations\/TFE3 gene fusion: Report of 5 cases and literature review","volume":"91","author":"Wang","year":"2019","journal-title":"Clin. Nephrol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105607_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100404","article-title":"Molecular characterization of TFE3-rearranged renal cell carcinoma: a comparative study with papillary and clear cell renal cell carcinomas","volume":"37","author":"Wei","year":"2024","journal-title":"Mod. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105607_bib70","first-page":"50","article-title":"Renal medullary carcinoma: a contemporary update","volume":"9","author":"Whaley","year":"2025","journal-title":"Kidney Cancer"},{"key":"10.1016\/j.critrevonc.2026.105607_bib71","article-title":"Urinary and Male Genital Tumours","volume":"8","author":"WHO Classification of Tumours Editorial Board","year":"2022"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105607_bib72","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1308\/rcsann.2020.0196","article-title":"SDH-deficient renal cell carcinoma: A clinicopathological analysis highlighting the role of genetic counselling","volume":"103","author":"Wilczek","year":"2021","journal-title":"Ann. R. Coll. Surg. Engl."},{"key":"10.1016\/j.critrevonc.2026.105607_bib73","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/modpathol.2014.86","article-title":"Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma","volume":"28","author":"Williamson","year":"2015","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105607_bib74","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.eururo.2022.05.029","article-title":"Genomic profiling and response to immune checkpoint inhibition plus tyrosine kinase inhibition in FH-deficient renal cell carcinoma","volume":"83","author":"Xu","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2026.105607_bib75","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41581-019-0210-z","article-title":"Oncometabolites in renal cancer","volume":"16","author":"Yong","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.critrevonc.2026.105607_bib76","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00345-025-05941-6","article-title":"Fumarate hydratase-deficient renal cell carcinoma: high intratumoral and peritumoral CD4-positive T cell infiltration density and high PD-L1 expression","volume":"43","author":"Yu","year":"2025","journal-title":"World J. Urol."},{"key":"10.1016\/j.critrevonc.2026.105607_bib77","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00428-023-03700-9","article-title":"Genomic alterations and diagnosis of renal cancer","volume":"484","author":"Zhang","year":"2024","journal-title":"Virchows Arch."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105607_bib78","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1001\/jamaoncol.2025.2497","article-title":"Sintilimab plus axitinib for advanced fumarate hydratase-deficient renal cell carcinoma: a phase 2 nonrandomized clinical trial","volume":"11","author":"Zhang","year":"2025","journal-title":"JAMA Oncol."},{"issue":"16_Suppl","key":"10.1016\/j.critrevonc.2026.105607_bib79","article-title":"Multi-omics analyses and molecular subtypes to provide potential therapeutic implications in fumarate hydratase\u2013deficient renal cell carcinoma","volume":"42","author":"Zhang","year":"2024","journal-title":"J. Clin. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:54:09Z","timestamp":1793087649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826004944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":79,"alternative-id":["S1040842826004944"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105607","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging patterns of kidney cancer in young adults: where do we stand?","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105607","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105607"}}